Vaccine after surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests an experimental vaccine (AST-201) given after surgery for advanced ovarian cancer. It aims to train your immune system to fight any remaining cancer cells and reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III ovarian, fallopian tube, or primary peritoneal cancer, and your surgery removed most of the cancer (any remaining tumor is smaller than 1 cm).
- You can start this additional therapy within 6 weeks after your surgery.
- Your tumor must have a specific genetic marker called 'HRP' (homologous recombination proficient), which your doctor can test for.
- You must be generally active and able to care for yourself (ECOG score 0 or 1).
- You must not have a history of autoimmune disease, active infections (like hepatitis B or C, HIV, or tuberculosis), or be on immune-suppressing medications.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
This trial tests a new combination of drugs given before surgery to shrink advanced ovarian cancer, which may make it easier to remove and improve outcomes. It includes an immunotherapy drug that helps your immune system fight cancer, along with standard chemotherapy.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
This trial tests a personalized vaccine made from your own tumor tissue called NeoOVSV. It is meant to train your immune system to fight any remaining cancer after surgery. The vaccine is a personal treatment because it uses your tumor's unique markers.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.